Nancy A. Simonian - 31 Mar 2023 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role
President & CEO, Director
Signature
/s/ Todd Rosenthal, as attorney-in-fact
Issuer symbol
SYRS
Transactions as of
31 Mar 2023
Net transactions value
-$4,778
Form type
4
Filing time
04 Apr 2023, 18:54:18 UTC
Previous filing
21 Feb 2023
Next filing
02 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SYRS Common Stock Options Exercise +6,000 +8.7% 75,272 31 Mar 2023 Direct F1, F2
transaction SYRS Common Stock Tax liability $4,778 -1,852 -2.5% $2.58 73,420 03 Apr 2023 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRS Restricted Stock Units Options Exercise $0 -6,000 -25% $0.000000 18,000 31 Mar 2023 Common Stock 6,000 Direct F2, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock received upon vesting of a restricted stock unit award.
F2 On September 16, 2022, the issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
F3 Represents shares used to cover tax withholding on a restricted stock unit release.
F4 Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F5 Represents a restricted stock unit award granted on February 15, 2022. These restricted stock units vest in four equal annual installments commencing on March 31, 2023.